Sylvain Bodard, Charles Dariane, Jean-Emmanuel Bibault, Idris Boudhabhay, Christophe Delavaud, Marc-Olivier Timsit, Virginie Verkarre, Arnaud Méjean, Olivier Hélénon, Sylvain Guinebert, Jean-Michel Correas
Managing a malignant renal tumor requires, first of all, a reflection on the necessity of its treatment. It must consider the renal function, altered at the time of diagnosis in 50% of cases. The treatment method chosen depends on many factors, in particular, the predicted residual renal function, the risk of chronic kidney disease, the need for temporary or long-term dialysis, and overall long-term survival. Other factors include the size, position, and number of tumors and a hereditary tumor background. When a renal-sparing management alternative is available, total nephrectomy should no longer be performed in patients with small malignant renal masses (cT1a)...
May 9, 2023: Bulletin du Cancer